Twice-Yearly Inclisiran Injection Shows Major LDL Reduction, Offering New Hope for Heart Patients
New clinical trial data published in July 2026 shows that inclisiran, a twice-yearly injectable cholesterol treatment, produces major reductions in low-density lipoprotein (LDL) cholesterol — the primary cardiovascular risk marker commonly called